Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + carboplatin + cisplatin + pemetrexed
- Development stage
- Preclinical
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of anlotinib (a multi-target tyrosine kinase inhibitor that inhibits angiogenesis by targeting VEGFR, PDGFR, FGFR, and c-Kit), carboplatin (a platinum-based chemotherapy agent), cisplatin (a platinum-based chemotherapy agent), and pemetrexed (a folate analog that inhibits multiple enzymes involved in folate metabolism and DNA synthesis). This combination likely aims to leverage multiple mechanisms of action for enhanced anti-tumor efficacy in advanced cancers, particularly non-small cell lung cancer.
02
Targets
GART (GAR transformylase)FGFR (FGFR family)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)DHFR (Dihydrofolate reductase)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)EGFR T790M (Epidermal growth factor receptor T790M mutant)KIT (c-KIT proto-oncogene receptor tyrosine kinase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on anlotinib + carboplatin + cisplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + carboplatin + cisplatin + pemetrexed.